Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00012207 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00012207 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 12 participants.
The verdict
NCT00012207, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of biological therapy after chemotherapy in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
Interventions
- DRUG prednisone
- DRUG cyclophosphamide
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL aldesleukin
- DRUG vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2000-09 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00012207
The ClinicalTrials.gov registry entry for NCT00012207 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which prednisone is the first listed.
NCT00012207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00012207 about?
NCT00012207 is a clinical study titled "Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more cancer cell...
What is the current status of trial NCT00012207?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2000-09. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00012207?
The interventions under investigation include: prednisone (DRUG), cyclophosphamide (DRUG), therapeutic autologous lymphocytes (BIOLOGICAL), aldesleukin (BIOLOGICAL), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00012207?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.